You are here

Article Text

Article menu
Download PDFPDF
Letter
Lack of efficacy of rituximab in Felty’s syndrome
  1. C Sordet,
  2. J-E Gottenberg,
  3. B Hellmich,
  4. P Kieffer,
  5. X Mariette,
  6. J Sibilia
  1. CHU Hautepierre Strasbourg, CHU Kremlin-Bicêtre, Paris 67098, France
  1. Correspondence to:
    Professor J Sibilia
    jean.sibiliawanadoo.fr

https://doi.org/10.1136/ard.2004.025643

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Felty’s syndrome (FS) is defined by the coexistence of rheumatoid arthritis (RA), neutropenia, and splenomegaly. The mechanisms underlying the neutropenia of FS may involve both cellular and humoral immunity, with a possible role of granulocyte-colony stimulating factor (G-CSF) antibodies.1 Various disease modifying antirheumatic drugs have been used to treat FS, but with varying success2 as this syndrome may arise in response to the excessive immune reaction found in RA. Interest has focused recently on a new biological tool in the treatment of RA, rituximab, a chimeric monoclonal antibody specific for human CD20 which targets B lymphocytes.3 Accordingly, we investigated here the safety and efficacy of rituximab in two patients presenting with active RA and severe and refractory FS.

    METHODS AND RESULTS

    Two men, …

    View Full Text